Prediction of acute coronary syndromes by urinary proteome analysis.
Identifieur interne : 000F32 ( PubMed/Corpus ); précédent : 000F31; suivant : 000F33Prediction of acute coronary syndromes by urinary proteome analysis.
Auteurs : Nay M. Htun ; Dianna J. Magliano ; Zhen-Yu Zhang ; Jasmine Lyons ; Thibault Petit ; Esther Nkuipou-Kenfack ; Adela Ramirez-Torres ; Constantin Von Zur Muhlen ; David Maahs ; Joost P. Schanstra ; Claudia Pontillo ; Martin Pejchinovski ; Janet K. Snell-Bergeon ; Christian Delles ; Harald Mischak ; Jan A. Staessen ; Jonathan E. Shaw ; Thomas Koeck ; Karlheinz PeterSource :
- PloS one [ 1932-6203 ] ; 2017.
English descriptors
- KwdEn :
- Acute Coronary Syndrome (diagnosis), Acute Coronary Syndrome (metabolism), Acute Coronary Syndrome (mortality), Acute Coronary Syndrome (urine), Age Factors, Aged, Area Under Curve, Biomarkers (urine), Case-Control Studies, Electrophoresis, Capillary, Female, Humans, Male, Mass Spectrometry, Middle Aged, Peptides (urine), Prognosis, Proteome (analysis), Proteomics, ROC Curve, Risk Factors, Support Vector Machine, Survival Analysis.
- MESH :
- chemical , analysis : Proteome.
- chemical , urine : Biomarkers, Peptides.
- diagnosis : Acute Coronary Syndrome.
- metabolism : Acute Coronary Syndrome.
- mortality : Acute Coronary Syndrome.
- urine : Acute Coronary Syndrome.
- Age Factors, Aged, Area Under Curve, Case-Control Studies, Electrophoresis, Capillary, Female, Humans, Male, Mass Spectrometry, Middle Aged, Prognosis, Proteomics, ROC Curve, Risk Factors, Support Vector Machine, Survival Analysis.
Abstract
Identification of individuals who are at risk of suffering from acute coronary syndromes (ACS) may allow to introduce preventative measures. We aimed to identify ACS-related urinary peptides, that combined as a pattern can be used as prognostic biomarker. Proteomic data of 252 individuals enrolled in four prospective studies from Australia, Europe and North America were analyzed. 126 of these had suffered from ACS within a period of up to 5 years post urine sampling (cases). Proteomic analysis of 84 cases and 84 matched controls resulted in the discovery of 75 ACS-related urinary peptides. Combining these to a peptide pattern, we established a prognostic biomarker named Acute Coronary Syndrome Predictor 75 (ACSP75). ACSP75 demonstrated reasonable prognostic discrimination (c-statistic = 0.664), which was similar to Framingham risk scoring (c-statistics = 0.644) in a validation cohort of 42 cases and 42 controls. However, generating by a composite algorithm named Acute Coronary Syndrome Composite Predictor (ACSCP), combining the biomarker pattern ACSP75 with the previously established urinary proteomic biomarker CAD238 characterizing coronary artery disease as the underlying aetiology, and age as a risk factor, further improved discrimination (c-statistic = 0.751) resulting in an added prognostic value over Framingham risk scoring expressed by an integrated discrimination improvement of 0.273 ± 0.048 (P < 0.0001) and net reclassification improvement of 0.405 ± 0.113 (P = 0.0007). In conclusion, we demonstrate that urinary peptide biomarkers have the potential to predict future ACS events in asymptomatic patients. Further large scale studies are warranted to determine the role of urinary biomarkers in clinical practice.
DOI: 10.1371/journal.pone.0172036
PubMed: 28273075
Links to Exploration step
pubmed:28273075Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prediction of acute coronary syndromes by urinary proteome analysis.</title><author><name sortKey="Htun, Nay M" sort="Htun, Nay M" uniqKey="Htun N" first="Nay M" last="Htun">Nay M. Htun</name><affiliation><nlm:affiliation>Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation><nlm:affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Zhen Yu" sort="Zhang, Zhen Yu" uniqKey="Zhang Z" first="Zhen-Yu" last="Zhang">Zhen-Yu Zhang</name><affiliation><nlm:affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Lyons, Jasmine" sort="Lyons, Jasmine" uniqKey="Lyons J" first="Jasmine" last="Lyons">Jasmine Lyons</name><affiliation><nlm:affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Petit, Thibault" sort="Petit, Thibault" uniqKey="Petit T" first="Thibault" last="Petit">Thibault Petit</name><affiliation><nlm:affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Nkuipou Kenfack, Esther" sort="Nkuipou Kenfack, Esther" uniqKey="Nkuipou Kenfack E" first="Esther" last="Nkuipou-Kenfack">Esther Nkuipou-Kenfack</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ramirez Torres, Adela" sort="Ramirez Torres, Adela" uniqKey="Ramirez Torres A" first="Adela" last="Ramirez-Torres">Adela Ramirez-Torres</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Von Zur Muhlen, Constantin" sort="Von Zur Muhlen, Constantin" uniqKey="Von Zur Muhlen C" first="Constantin" last="Von Zur Muhlen">Constantin Von Zur Muhlen</name><affiliation><nlm:affiliation>Department of Cardiology, University Heart Centre Freiburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Maahs, David" sort="Maahs, David" uniqKey="Maahs D" first="David" last="Maahs">David Maahs</name><affiliation><nlm:affiliation>Department of Paediatrics, Stanford School of Medicine, Stanford, California, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Schanstra, Joost P" sort="Schanstra, Joost P" uniqKey="Schanstra J" first="Joost P" last="Schanstra">Joost P. Schanstra</name><affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pontillo, Claudia" sort="Pontillo, Claudia" uniqKey="Pontillo C" first="Claudia" last="Pontillo">Claudia Pontillo</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pejchinovski, Martin" sort="Pejchinovski, Martin" uniqKey="Pejchinovski M" first="Martin" last="Pejchinovski">Martin Pejchinovski</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Snell Bergeon, Janet K" sort="Snell Bergeon, Janet K" uniqKey="Snell Bergeon J" first="Janet K" last="Snell-Bergeon">Janet K. Snell-Bergeon</name><affiliation><nlm:affiliation>Barbara Davis Centre for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Delles, Christian" sort="Delles, Christian" uniqKey="Delles C" first="Christian" last="Delles">Christian Delles</name><affiliation><nlm:affiliation>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Mischak, Harald" sort="Mischak, Harald" uniqKey="Mischak H" first="Harald" last="Mischak">Harald Mischak</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Staessen, Jan A" sort="Staessen, Jan A" uniqKey="Staessen J" first="Jan A" last="Staessen">Jan A. Staessen</name><affiliation><nlm:affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation><nlm:affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Koeck, Thomas" sort="Koeck, Thomas" uniqKey="Koeck T" first="Thomas" last="Koeck">Thomas Koeck</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Peter, Karlheinz" sort="Peter, Karlheinz" uniqKey="Peter K" first="Karlheinz" last="Peter">Karlheinz Peter</name><affiliation><nlm:affiliation>Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28273075</idno><idno type="pmid">28273075</idno><idno type="doi">10.1371/journal.pone.0172036</idno><idno type="wicri:Area/PubMed/Corpus">000F32</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F32</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prediction of acute coronary syndromes by urinary proteome analysis.</title><author><name sortKey="Htun, Nay M" sort="Htun, Nay M" uniqKey="Htun N" first="Nay M" last="Htun">Nay M. Htun</name><affiliation><nlm:affiliation>Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Magliano, Dianna J" sort="Magliano, Dianna J" uniqKey="Magliano D" first="Dianna J" last="Magliano">Dianna J. Magliano</name><affiliation><nlm:affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Zhen Yu" sort="Zhang, Zhen Yu" uniqKey="Zhang Z" first="Zhen-Yu" last="Zhang">Zhen-Yu Zhang</name><affiliation><nlm:affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Lyons, Jasmine" sort="Lyons, Jasmine" uniqKey="Lyons J" first="Jasmine" last="Lyons">Jasmine Lyons</name><affiliation><nlm:affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Petit, Thibault" sort="Petit, Thibault" uniqKey="Petit T" first="Thibault" last="Petit">Thibault Petit</name><affiliation><nlm:affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Nkuipou Kenfack, Esther" sort="Nkuipou Kenfack, Esther" uniqKey="Nkuipou Kenfack E" first="Esther" last="Nkuipou-Kenfack">Esther Nkuipou-Kenfack</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ramirez Torres, Adela" sort="Ramirez Torres, Adela" uniqKey="Ramirez Torres A" first="Adela" last="Ramirez-Torres">Adela Ramirez-Torres</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Von Zur Muhlen, Constantin" sort="Von Zur Muhlen, Constantin" uniqKey="Von Zur Muhlen C" first="Constantin" last="Von Zur Muhlen">Constantin Von Zur Muhlen</name><affiliation><nlm:affiliation>Department of Cardiology, University Heart Centre Freiburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Maahs, David" sort="Maahs, David" uniqKey="Maahs D" first="David" last="Maahs">David Maahs</name><affiliation><nlm:affiliation>Department of Paediatrics, Stanford School of Medicine, Stanford, California, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Schanstra, Joost P" sort="Schanstra, Joost P" uniqKey="Schanstra J" first="Joost P" last="Schanstra">Joost P. Schanstra</name><affiliation><nlm:affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Pontillo, Claudia" sort="Pontillo, Claudia" uniqKey="Pontillo C" first="Claudia" last="Pontillo">Claudia Pontillo</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Pejchinovski, Martin" sort="Pejchinovski, Martin" uniqKey="Pejchinovski M" first="Martin" last="Pejchinovski">Martin Pejchinovski</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Snell Bergeon, Janet K" sort="Snell Bergeon, Janet K" uniqKey="Snell Bergeon J" first="Janet K" last="Snell-Bergeon">Janet K. Snell-Bergeon</name><affiliation><nlm:affiliation>Barbara Davis Centre for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States of America.</nlm:affiliation></affiliation></author><author><name sortKey="Delles, Christian" sort="Delles, Christian" uniqKey="Delles C" first="Christian" last="Delles">Christian Delles</name><affiliation><nlm:affiliation>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Mischak, Harald" sort="Mischak, Harald" uniqKey="Mischak H" first="Harald" last="Mischak">Harald Mischak</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Staessen, Jan A" sort="Staessen, Jan A" uniqKey="Staessen J" first="Jan A" last="Staessen">Jan A. Staessen</name><affiliation><nlm:affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Shaw, Jonathan E" sort="Shaw, Jonathan E" uniqKey="Shaw J" first="Jonathan E" last="Shaw">Jonathan E. Shaw</name><affiliation><nlm:affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Koeck, Thomas" sort="Koeck, Thomas" uniqKey="Koeck T" first="Thomas" last="Koeck">Thomas Koeck</name><affiliation><nlm:affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Peter, Karlheinz" sort="Peter, Karlheinz" uniqKey="Peter K" first="Karlheinz" last="Peter">Karlheinz Peter</name><affiliation><nlm:affiliation>Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</nlm:affiliation></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Coronary Syndrome (diagnosis)</term><term>Acute Coronary Syndrome (metabolism)</term><term>Acute Coronary Syndrome (mortality)</term><term>Acute Coronary Syndrome (urine)</term><term>Age Factors</term><term>Aged</term><term>Area Under Curve</term><term>Biomarkers (urine)</term><term>Case-Control Studies</term><term>Electrophoresis, Capillary</term><term>Female</term><term>Humans</term><term>Male</term><term>Mass Spectrometry</term><term>Middle Aged</term><term>Peptides (urine)</term><term>Prognosis</term><term>Proteome (analysis)</term><term>Proteomics</term><term>ROC Curve</term><term>Risk Factors</term><term>Support Vector Machine</term><term>Survival Analysis</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Proteome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="urine" xml:lang="en"><term>Biomarkers</term><term>Peptides</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" qualifier="urine" xml:lang="en"><term>Acute Coronary Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Age Factors</term><term>Aged</term><term>Area Under Curve</term><term>Case-Control Studies</term><term>Electrophoresis, Capillary</term><term>Female</term><term>Humans</term><term>Male</term><term>Mass Spectrometry</term><term>Middle Aged</term><term>Prognosis</term><term>Proteomics</term><term>ROC Curve</term><term>Risk Factors</term><term>Support Vector Machine</term><term>Survival Analysis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Identification of individuals who are at risk of suffering from acute coronary syndromes (ACS) may allow to introduce preventative measures. We aimed to identify ACS-related urinary peptides, that combined as a pattern can be used as prognostic biomarker. Proteomic data of 252 individuals enrolled in four prospective studies from Australia, Europe and North America were analyzed. 126 of these had suffered from ACS within a period of up to 5 years post urine sampling (cases). Proteomic analysis of 84 cases and 84 matched controls resulted in the discovery of 75 ACS-related urinary peptides. Combining these to a peptide pattern, we established a prognostic biomarker named Acute Coronary Syndrome Predictor 75 (ACSP75). ACSP75 demonstrated reasonable prognostic discrimination (c-statistic = 0.664), which was similar to Framingham risk scoring (c-statistics = 0.644) in a validation cohort of 42 cases and 42 controls. However, generating by a composite algorithm named Acute Coronary Syndrome Composite Predictor (ACSCP), combining the biomarker pattern ACSP75 with the previously established urinary proteomic biomarker CAD238 characterizing coronary artery disease as the underlying aetiology, and age as a risk factor, further improved discrimination (c-statistic = 0.751) resulting in an added prognostic value over Framingham risk scoring expressed by an integrated discrimination improvement of 0.273 ± 0.048 (P < 0.0001) and net reclassification improvement of 0.405 ± 0.113 (P = 0.0007). In conclusion, we demonstrate that urinary peptide biomarkers have the potential to predict future ACS events in asymptomatic patients. Further large scale studies are warranted to determine the role of urinary biomarkers in clinical practice.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28273075</PMID><DateCreated><Year>2017</Year><Month>03</Month><Day>08</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Prediction of acute coronary syndromes by urinary proteome analysis.</ArticleTitle><Pagination><MedlinePgn>e0172036</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0172036</ELocationID><Abstract><AbstractText>Identification of individuals who are at risk of suffering from acute coronary syndromes (ACS) may allow to introduce preventative measures. We aimed to identify ACS-related urinary peptides, that combined as a pattern can be used as prognostic biomarker. Proteomic data of 252 individuals enrolled in four prospective studies from Australia, Europe and North America were analyzed. 126 of these had suffered from ACS within a period of up to 5 years post urine sampling (cases). Proteomic analysis of 84 cases and 84 matched controls resulted in the discovery of 75 ACS-related urinary peptides. Combining these to a peptide pattern, we established a prognostic biomarker named Acute Coronary Syndrome Predictor 75 (ACSP75). ACSP75 demonstrated reasonable prognostic discrimination (c-statistic = 0.664), which was similar to Framingham risk scoring (c-statistics = 0.644) in a validation cohort of 42 cases and 42 controls. However, generating by a composite algorithm named Acute Coronary Syndrome Composite Predictor (ACSCP), combining the biomarker pattern ACSP75 with the previously established urinary proteomic biomarker CAD238 characterizing coronary artery disease as the underlying aetiology, and age as a risk factor, further improved discrimination (c-statistic = 0.751) resulting in an added prognostic value over Framingham risk scoring expressed by an integrated discrimination improvement of 0.273 ± 0.048 (P < 0.0001) and net reclassification improvement of 0.405 ± 0.113 (P = 0.0007). In conclusion, we demonstrate that urinary peptide biomarkers have the potential to predict future ACS events in asymptomatic patients. Further large scale studies are warranted to determine the role of urinary biomarkers in clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Htun</LastName><ForeName>Nay M</ForeName><Initials>NM</Initials><AffiliationInfo><Affiliation>Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magliano</LastName><ForeName>Dianna J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhen-Yu</ForeName><Initials>ZY</Initials><AffiliationInfo><Affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petit</LastName><ForeName>Thibault</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nkuipou-Kenfack</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez-Torres</LastName><ForeName>Adela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Zur Muhlen</LastName><ForeName>Constantin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University Heart Centre Freiburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maahs</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, Stanford School of Medicine, Stanford, California, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barbara Davis Centre for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schanstra</LastName><ForeName>Joost P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Institut National de la Santé et de la Recherche Médicale (INSERM), U1048, Institut of Cardiovascular and Metabolic Disease, Toulouse, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Université Toulouse III Paul-Sabatier, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pontillo</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pejchinovski</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Snell-Bergeon</LastName><ForeName>Janet K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Barbara Davis Centre for Diabetes, University of Colorado School of Medicine, Aurora, Colorado, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delles</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mischak</LastName><ForeName>Harald</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staessen</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>R&D VitaK Group, Maastricht University, Maastricht, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Jonathan E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Clinical Diabetes and Epidemiology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeck</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Mosaiques Diagnostics GmbH, Hanover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peter</LastName><ForeName>Karlheinz</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Atherothrombosis and Vascular Biology, Baker IDI Heart and Diabetes Institute, Melbourne, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010455">Peptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Proteomics. 2008 Feb;7(2):290-8</RefSource><PMID Version="1">17951555</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Rheumatol. 1998;17(3):234-5</RefSource><PMID Version="1">9694059</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biomed Res. 2014 Jan;28(1):25-39</RefSource><PMID Version="1">24474961</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hypertens. 2010 Nov;28(11):2316-22</RefSource><PMID Version="1">20811296</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Proteomics. 2009 Oct;8(10):2296-307</RefSource><PMID Version="1">19564150</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2006 Mar;7(3):230-40</RefSource><PMID Version="1">16510332</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vasc Health Risk Manag. 2013;9:435-56</RefSource><PMID Version="1">23983474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proteomics Clin Appl. 2015 Jun;9(5-6):453-68</RefSource><PMID Version="1">25641766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2016 Nov 1;134(18):1328-1338</RefSource><PMID Version="1">27682886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circulation. 2008 Feb 12;117(6):743-53</RefSource><PMID Version="1">18212285</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rapid Commun Mass Spectrom. 2004;18(2):149-56</RefSource><PMID Version="1">14745763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2008 Jul;19(7):1283-90</RefSource><PMID Version="1">18448586</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ageing Res Rev. 2014 Nov;18:74-85</RefSource><PMID Version="1">25257180</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proteomics Clin Appl. 2008 Jul 10;2(7-8):964</RefSource><PMID Version="1">20130789</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2014 Nov 7;35(42):2972-9</RefSource><PMID Version="1">24742886</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Soc Nephrol. 2015 Aug;26(8):1999-2010</RefSource><PMID Version="1">25589610</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hypertension. 2015 Jul;66(1):52-60</RefSource><PMID Version="1">26063667</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Vasc Med. 2009 Feb;14(1):73-89</RefSource><PMID Version="1">19144782</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Transl Med. 2013 Oct 16;11:260</RefSource><PMID Version="1">24131807</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12</RefSource><PMID Version="1">17569110</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Res Clin Pract. 2002 Aug;57(2):119-29</RefSource><PMID Version="1">12062857</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 May 27;367(9524):1747-57</RefSource><PMID Version="1">16731270</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drug Discov Today Technol. 2006 Spring;3(1):13-9</RefSource><PMID Version="1">24980097</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Interact Cardiovasc Thorac Surg. 2013 Jan;16(1):11-5</RefSource><PMID Version="1">23049084</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Transl Med. 2012 Jul 06;10:140</RefSource><PMID Version="1">22768802</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Methods Mol Biol. 2009;564:105-21</RefSource><PMID Version="1">19544019</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Lipidol. 2014 Oct;25(5):394-9</RefSource><PMID Version="1">25137612</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):939-45</RefSource><PMID Version="1">24526693</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 1;877(13):1250-8</RefSource><PMID Version="1">19010091</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Proteome Res. 2009 Jan;8(1):335-45</RefSource><PMID Version="1">19053529</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Cell Proteomics. 2012 Jul;11(7):M111.013847</RefSource><PMID Version="1">22371488</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Lipidol. 2014 Oct;25(5):358-66</RefSource><PMID Version="1">25089553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2015 May 1;36(17 ):1049-58</RefSource><PMID Version="1">24553721</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Electrophoresis. 2005 Apr;26(7-8):1476-87</RefSource><PMID Version="1">15765478</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Atherosclerosis. 2015 May;240(1):26-32</RefSource><PMID Version="1">25746374</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cardiol. 2014 Sep;176(1):158-65</RefSource><PMID Version="1">25065337</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biomark Insights. 2008 Mar 12;3:101-113</RefSource><PMID Version="1">19578499</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Heart Assoc. 2013 Nov 15;2(6):e000307</RefSource><PMID Version="1">24242683</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Circ Res. 2013 Jul 19;113(3):252-65</RefSource><PMID Version="1">23748430</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proteomics Clin Appl. 2015 Jun;9(5-6):610-7</RefSource><PMID Version="1">25786980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Heart J. 2015 Oct 14;36(39):2635-42</RefSource><PMID Version="1">26049157</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiol Rev. 2013 Nov-Dec;21(6):270-88</RefSource><PMID Version="1">23422022</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Hypertens. 2012 Jan;30(1):67-74</RefSource><PMID Version="1">22134387</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cardiovasc Pathol. 2013 Sep-Oct;22(5):401-7</RefSource><PMID Version="1">23375582</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D054058" MajorTopicYN="N">Acute Coronary Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019075" MajorTopicYN="N">Electrophoresis, Capillary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010455" MajorTopicYN="N">Peptides</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="Y">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060388" MajorTopicYN="N">Support Vector Machine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>01</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28273075</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0172036</ArticleId><ArticleId IdType="pii">PONE-D-16-45061</ArticleId><ArticleId IdType="pmc">PMC5342174</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F32 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000F32 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:28273075
|texte= Prediction of acute coronary syndromes by urinary proteome analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:28273075" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |